Trial Profile

Phase IIb trial of ATL 1102 in patients with multiple sclerosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATL 1102 (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Sponsors Antisense Therapeutics

Most Recent Events

24 Oct 2014 According to Antisense Therapeutics media release, US FDA has responded affirmatively to the Company plan to submit a U.S. Investigational New Drug (IND) application for initiation of this phase II trial.
19 Aug 2014 Antisense Therapeutics has submitted a formal request for the US FDA's assessment of ANP's plans for a Phase IIb trial of ATL1102 in MS patients.
19 Mar 2013 Planned initiation date changed to 1 Jan 2014, based on information in an Antisense Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com